Humacyte To Participate in Upcoming Investor Conferences
MWN-AI** Summary
Humacyte, Inc. (Nasdaq: HUMA), a biotechnology firm focused on developing bioengineered human tissues for medical applications, has announced its participation in two key investor conferences in March 2026. The management team will present at the TD Cowen 46th Annual Healthcare Conference on March 4, 2026, at 10:30 AM ET, followed by a fireside chat at the Barclays 28th Annual Global Healthcare Conference on the same day from 1:00 PM to 1:25 PM ET. Investors and interested parties can access these events via provided webcast links.
Humacyte is making strides in the field of regenerative medicine, having developed a pioneering technology that creates universally implantable, acellular human tissues. The company received FDA approval for its Biologics License Application for Symvess, an acellular tissue-engineered vessel (ATEV), aimed at treating vascular trauma. The product has also been designated as a Regenerative Medicine Advanced Therapy (RMAT) and is undergoing late-stage clinical trials for further vascular applications, including treatments for arteriovenous access in hemodialysis and peripheral artery disease.
In addition to its current product portfolio, Humacyte is exploring preclinical developments for applications in coronary artery bypass grafting, pediatric heart surgery, and type 1 diabetes treatments. With a commitment to improving patient outcomes through innovation, Humacyte aims to transform therapeutic strategies in medicine.
Forward-looking statements in Humacyte’s communications express optimism about the commercialization of its products, albeit with associated risks and potential uncertainties inherent in the biotechnology field. The company urges stakeholders to consider these factors when evaluating its future prospects. For more information, interested parties can visit Humacyte's official website at www.Humacyte.com.
MWN-AI** Analysis
Humacyte, Inc. (Nasdaq: HUMA) has gained significant investor attention lately, and its upcoming participation in key investor conferences presents a strategic opportunity for stakeholders and potential investors. The TD Cowen 46th Annual Healthcare Conference and Barclays 28th Annual Global Healthcare Conference, scheduled for early March, will showcase Humacyte's advancements in developing universally implantable bioengineered tissues. These venues provide critical platforms for the company to highlight its recent FDA approval of the acellular tissue engineered vessel (ATEV) for vascular trauma and discuss its ongoing clinical trials targeting various vascular conditions.
Analysts should closely monitor the discourse during these conferences, as new insights may surface regarding the commercialization timeline for Humacyte's flagship product, Symvess. The continued FDA support through RMAT and Fast Track designations underscores the potential for these products to fill significant gaps in current medical treatments.
Given the ongoing clinical developments spanning coronary artery bypass grafts and pediatric heart surgeries, investors should be attentive to updates that could affect future valuations. Notably, the presence of FDA priority designations can spur up investor confidence, as these products could soon become essential treatment options, potentially driving significant revenue streams.
Moreover, the biotechnology sector is inherently volatile, and while Humacyte has laid a robust groundwork, investors must remain cognizant of the operational risks highlighted in its forward-looking statements. As developments unfold post-conference, assessing market responses to management's insights on product pipeline advancements, manufacturing capabilities, and market acceptance will be crucial for determining Humacyte’s trajectory.
In conclusion, attending or following Humacyte’s conference presentations can yield valuable, actionable insights, presenting a sound investment strategy tailored to the emerging biotechnology landscape. Stay informed on market trends and readiness to capitalize on opportunities as they arise.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
DURHAM, N.C., March 02, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that the Company’s management team will be participating in the following investor conferences during the month of March.
TD Cowen 46th Annual Healthcare Conference
Presentation: Wednesday March 4, 2026, 10:30-11:00 am Eastern Time
Webcast Link: Click Here
Barclays 28th Annual Global Healthcare Conference
Presentation: Fireside Chat Time 1:00-1:25 pm Eastern Time
Webcast Link: Click Here
About Humacyte
Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues, advanced tissue constructs, and organ systems designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Humacyte’s Biologics License Application for Symvess, the acellular tissue engineered vessel (ATEV), in the vascular trauma indication was approved by the FDA in December 2024. ATEVs are also currently in late-stage clinical trials targeting other vascular applications, including arteriovenous (AV) access for hemodialysis and peripheral artery disease (PAD). Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte’s 6mm ATEV for AV access in hemodialysis was the first product candidate to receive the FDA’s Regenerative Medicine Advanced Therapy (RMAT) designation and has also received FDA Fast Track designation. Humacyte’s 6mm ATEV for urgent arterial repair following extremity vascular trauma and for advanced PAD also have received RMAT designations. The ATEV received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense. For more information, visit www.Humacyte.com.
For uses other than the FDA approval in the extremity vascular trauma indication, the ATEV is an investigational product and has not been approved for sale by the FDA or any other regulatory agency.
Forward-Looking Statements
This press release contains forward-looking statements that are based on beliefs and assumptions and on information currently available. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties, and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. Forward-looking statements in this press release include, but are not limited to, our plans and ability to commercialize Symvess and, if approved by regulatory authorities, our product candidates, successfully and on our anticipated timelines; the degree of market acceptance of and the availability of third-party coverage and reimbursement for Symvess and, if approved by regulatory authorities, our product candidates; our ability to manufacture Symvess and, if approved by regulatory authorities, our product candidates in sufficient quantities to satisfy our clinical trial and commercial needs; the anticipated benefits of our ATEVs relative to existing alternatives; our plans and ability to execute product development, process development and preclinical development efforts successfully and on our anticipated timelines; our ability to design, initiate and successfully complete clinical trials and other studies for our product candidates and our plans and expectations regarding our ongoing or planned clinical trials; the anticipated characteristics and performance of our ATEVs; the implementation of our business model and strategic plans for our business; our ability to execute and achieve the expected benefits of our cost-saving measures and whether our efforts will result in further actions or additional asset impairment charges that adversely affect our business; and the timing or likelihood of regulatory filings, acceptances and approvals. We cannot assure you that the forward-looking statements in this press release will prove to be accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results, including, among others, changes in applicable laws or regulations, the possibility that Humacyte may be adversely affected by other economic, business, competitive and/or reputational factors, and other risks and uncertainties, including those described under the header “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2024 and Form 10-Q for the quarter ended September 30, 2025, each filed by Humacyte with the SEC, and in future SEC filings. Most of these factors are outside of Humacyte’s control and are difficult to predict. Furthermore, if the forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. Except as required by law, we have no current intention of updating any of the forward-looking statements in this press release. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.
Humacyte Investor Contact:
Joyce Allaire
LifeSci Advisors LLC
+1-617-435-6602
jallaire@lifesciadvisors.com
investors@humacyte.com
Humacyte Media Contact:
Rich Luchette
Precision Strategies
+1-202-845-3924
rich@precisionstrategies.com
media@humacyte.com
FAQ**
How does Humacyte Inc. (HUMA) plan to address the market acceptance and reimbursement challenges for its recently approved product, Symvess?
What specific timelines does Humacyte Inc. (HUMA) anticipate for the commercialization of its acellular tissue engineered vessels (ATEVs) in various applications?
Can Humacyte Inc. (HUMA) elaborate on the risks and uncertainties it faces that may impact its ability to meet the projected timelines for clinical trials and regulatory approvals?
What competitive advantages does Humacyte Inc. (HUMA) believe its bioengineered human tissues have over traditional treatment options in the vascular trauma and other indications?
**MWN-AI FAQ is based on asking OpenAI questions about Humacyte Inc. (NASDAQ: HUMA).
NASDAQ: HUMA
HUMA Trading
4.03% G/L:
$1.265 Last:
4,307,770 Volume:
$1.22 Open:
